ARTICLE | Clinical News
Inhaled alpha-1 antitrypsin regulatory update
April 4, 2016 7:00 AM UTC
EMA accepted for review an MAA from Kamada for inhaled alpha-1 antitrypsin (AAT) to treat AAT deficiency. The MAA is based on a Phase II/III trial in 168 patients in which twice-daily inhaled AAT miss...